Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China

AIM: That clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Sini, Peng, Liubao, Tan, Chongqing, Zeng, Xiaohui, Wan, Xiaomin, Luo, Xia, Yi, Lidan, Li, Jianhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205241/
https://www.ncbi.nlm.nih.gov/pubmed/32379763
http://dx.doi.org/10.1371/journal.pone.0232240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205241/
https://www.ncbi.nlm.nih.gov/pubmed/32379763
http://dx.doi.org/10.1371/journal.pone.0232240

Ejemplares similares